Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: Mavenclad
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: EMD Serono
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
The arrangement aims to provide financial compensation for Blue Plans that is dependent on the rate at which their members discontinue the two-year treatment with MAVENCLAD or switch to a different MS therapy at any point over the typical course of treatment.